Divalproex Sodium Tablet, Delayed Release
Product Images NDC 70518-3055

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-3055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium 250mg 70518 3055 01

Divalproex Sodium 250 mg delayed-release oral tablets in a package of 100 tablets. The label shows the product name, strength, dosage form, and quantity, repackaged by RemedyRepack Inc. It includes a QR code, manufacturer information (Rising Pharma, Inc., Allendale, NJ), and storage directions.*

FDA Label Image

Divalproex Sodium 250mg 70518 3055 02

Label for Divalproex Sodium delayed-release tablet, 250 mg, single tablet quantity. The label includes the NDC 70518-3055-02, repackaged by RemedyRepack Inc., with manufacturer Rising Pharma, Inc. It features dosage form and strength, storage instructions, and a QR code on a white background with purple accents.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Divalproex Sodium 250 mg delayed-release oral tablets. The label indicates a quantity of 30 tablets and specifies that the product is prescription only (RX ONLY). It includes the NDC number 70518-3055-00 and repackaging information by RemedyRepack Inc., Indiana, PA. The manufacturer is noted as Rising Pharma, Inc., Allendale, NJ.*

FDA Label Image

Figure 1 (Divalproex Fig1)

A bar chart comparing the efficacy percentages of placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) in two studies, with Study 1 measured by YMRS and Study 2 by MRS. The chart shows higher response percentages for DVPX (60% and 58%) compared to placebo (26% and 29%), with statistical significance indicated (p < 0.05).*

FDA Label Image

Figure 2 (Divalproex Fig2)

A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium Delayed-Release Tablets and placebo across a patient population percentage. The vertical axis shows percent change with labels for improvement and worsening, while the horizontal axis shows the percentage of patients from 0% to 100%. The solid line represents Divalproex Sodium Delayed-Release Tablets, showing generally greater improvement, and the dotted line represents placebo.*

FDA Label Image

Figure 3 (Divalproex Fig3)

A line graph titled Figure 3 depicting the % reduction in CRS rate on the vertical axis and % of patients on the horizontal axis. Two lines compare High Dose and Low Dose groups, illustrating patient response distribution from worsening to improvement.*

FDA Label Image

Figure 4 (Divalproex Fig4)

Bar chart titled 'Mean 4-week Migraine Rates' compares migraine rates between placebo and Divalproex Sodium delayed-release tablets in two clinical studies. The vertical axis measures migraine rates from 0 to 6. Study 1 shows higher migraine rates for placebo than for Divalproex Sodium at a mean dose of 1,087 mg/day. Study 2 shows similar trends with doses of 500 or 1,000 mg/day.*

FDA Label Image

Chemical Structure (Divalproex Str)

Chemical structure of Divalproex Sodium showing a polymeric structure with branched alkyl chains, carboxylate groups, and sodium ion. The diagram depicts repeating units indicated by 'n' representing the polymer nature of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.